347 related articles for article (PubMed ID: 29472724)
21. Clonal dynamics in a case of acute monoblastic leukemia that later developed myeloproliferative neoplasm.
Sato S; Itonaga H; Taguchi M; Sawayama Y; Imanishi D; Tsushima H; Hata T; Moriuchi Y; Mishima H; Kinoshita A; Yoshiura KI; Miyazaki Y
Int J Hematol; 2018 Aug; 108(2):213-217. PubMed ID: 29417354
[TBL] [Abstract][Full Text] [Related]
22. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
23. Analysis of FLT3-Activating Mutations in Patients With Acute Myelogenous Leukemia in Jordan: Association With FAB Subtypes and Identification of Subgroups With Poor Prognosis.
Halahleh K; Taqash A; Abdelkhaleq H; Manasrah M; Marie L; Al-Rabi K
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):e588-e597. PubMed ID: 33811005
[TBL] [Abstract][Full Text] [Related]
24. Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia.
Itzykson R; Duployez N; Fasan A; Decool G; Marceau-Renaut A; Meggendorfer M; Jourdan E; Petit A; Lapillonne H; Micol JB; Cornillet-Lefebvre P; Ifrah N; Leverger G; Dombret H; Boissel N; Haferlach T; Preudhomme C
Blood; 2018 Jul; 132(2):187-196. PubMed ID: 29692343
[TBL] [Abstract][Full Text] [Related]
25. Persistent DNMT3A mutation burden in DNMT3A mutated adult cytogenetically normal acute myeloid leukemia patients in long-term remission.
Sun Y; Shen H; Xu T; Yang Z; Qiu H; Sun A; Chen S; Wu D; Xu Y
Leuk Res; 2016 Oct; 49():102-7. PubMed ID: 27626217
[TBL] [Abstract][Full Text] [Related]
26. The impact of minimal residual disease prior to unmanipulated haploidentical hematopoietic stem cell transplantation in patients with acute myeloid leukemia in complete remission.
Zhao XS; Qin YZ; Liu YR; Chang YJ; Xu LP; Zhang XH; Huang XJ
Leuk Lymphoma; 2017 May; 58(5):1135-1143. PubMed ID: 27733089
[TBL] [Abstract][Full Text] [Related]
27. Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse.
Press RD; Eickelberg G; Froman A; Yang F; Stentz A; Flatley EM; Fan G; Lim JY; Meyers G; Maziarz RT; Cook RJ
Am J Hematol; 2019 Aug; 94(8):902-912. PubMed ID: 31124175
[TBL] [Abstract][Full Text] [Related]
28. Clinical Utility of Next-Generation Sequencing for Oncogenic Mutations in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation.
Luskin MR; Carroll M; Lieberman D; Morrissette JJD; Zhao J; Crisalli L; Roth DB; Luger SM; Porter DL; Reshef R
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1961-1967. PubMed ID: 27478011
[TBL] [Abstract][Full Text] [Related]
29. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.
Thol F; Gabdoulline R; Liebich A; Klement P; Schiller J; Kandziora C; Hambach L; Stadler M; Koenecke C; Flintrop M; Pankratz M; Wichmann M; Neziri B; Büttner K; Heida B; Klesse S; Chaturvedi A; Kloos A; Göhring G; Schlegelberger B; Gaidzik VI; Bullinger L; Fiedler W; Heim A; Hamwi I; Eder M; Krauter J; Schlenk RF; Paschka P; Döhner K; Döhner H; Ganser A; Heuser M
Blood; 2018 Oct; 132(16):1703-1713. PubMed ID: 30190321
[TBL] [Abstract][Full Text] [Related]
30. Survival differences and associated molecular signatures of DNMT3A-mutant acute myeloid leukemia patients.
Lauber C; Correia N; Trumpp A; Rieger MA; Dolnik A; Bullinger L; Roeder I; Seifert M
Sci Rep; 2020 Jul; 10(1):12761. PubMed ID: 32728112
[TBL] [Abstract][Full Text] [Related]
31. ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group.
Paschka P; Schlenk RF; Gaidzik VI; Herzig JK; Aulitzky T; Bullinger L; Späth D; Teleanu V; Kündgen A; Köhne CH; Brossart P; Held G; Horst HA; Ringhoffer M; Götze K; Nachbaur D; Kindler T; Heuser M; Thol F; Ganser A; Döhner H; Döhner K
Haematologica; 2015 Mar; 100(3):324-30. PubMed ID: 25596267
[TBL] [Abstract][Full Text] [Related]
32. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia.
Krönke J; Bullinger L; Teleanu V; Tschürtz F; Gaidzik VI; Kühn MW; Rücker FG; Holzmann K; Paschka P; Kapp-Schwörer S; Späth D; Kindler T; Schittenhelm M; Krauter J; Ganser A; Göhring G; Schlegelberger B; Schlenk RF; Döhner H; Döhner K
Blood; 2013 Jul; 122(1):100-8. PubMed ID: 23704090
[TBL] [Abstract][Full Text] [Related]
33. Quantitative detection of DNMT3A R882H mutation in acute myeloid leukemia.
Berenstein R; Blau IW; Suckert N; Baldus C; Pezzutto A; Dörken B; Blau O
J Exp Clin Cancer Res; 2015 May; 34(1):55. PubMed ID: 25994761
[TBL] [Abstract][Full Text] [Related]
34. Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation.
Chen Y; Cortes J; Estrov Z; Faderl S; Qiao W; Abruzzo L; Garcia-Manero G; Pierce S; Huang X; Kebriaei P; Kadia T; De Lima M; Kantarjian H; Ravandi F
J Clin Oncol; 2011 Jun; 29(18):2507-13. PubMed ID: 21555694
[TBL] [Abstract][Full Text] [Related]
35. Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations.
Devillier R; Gelsi-Boyer V; Brecqueville M; Carbuccia N; Murati A; Vey N; Birnbaum D; Mozziconacci MJ
Am J Hematol; 2012 Jul; 87(7):659-62. PubMed ID: 22535592
[TBL] [Abstract][Full Text] [Related]
36. Effect of DNMT3A variant allele frequency and double mutation on clinicopathologic features of patients with de novo AML.
Narayanan D; Pozdnyakova O; Hasserjian RP; Patel SS; Weinberg OK
Blood Adv; 2021 Jun; 5(11):2539-2549. PubMed ID: 34100902
[TBL] [Abstract][Full Text] [Related]
37. DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia.
Gaidzik VI; Weber D; Paschka P; Kaumanns A; Krieger S; Corbacioglu A; Krönke J; Kapp-Schwoerer S; Krämer D; Horst HA; Schmidt-Wolf I; Held G; Kündgen A; Ringhoffer M; Götze K; Kindler T; Fiedler W; Wattad M; Schlenk RF; Bullinger L; Teleanu V; Schlegelberger B; Thol F; Heuser M; Ganser A; Döhner H; Döhner K;
Leukemia; 2018 Jan; 32(1):30-37. PubMed ID: 28643785
[TBL] [Abstract][Full Text] [Related]
38. DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications.
Hou HA; Kuo YY; Liu CY; Chou WC; Lee MC; Chen CY; Lin LI; Tseng MH; Huang CF; Chiang YC; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF
Blood; 2012 Jan; 119(2):559-68. PubMed ID: 22077061
[TBL] [Abstract][Full Text] [Related]
39. Identification of Cell Type-Specific Effects of
Bae SG; Kim HJ; Kim MY; Kim DDH; Shin SI; Ahn JS; Park J
Mol Cells; 2023 Oct; 46(10):611-626. PubMed ID: 37853686
[TBL] [Abstract][Full Text] [Related]
40. Therapy-related acute myeloid leukemia developing 14 years after allogeneic hematopoietic stem cell transplantation, from a persistent R882H-DNMT3A mutated clone of patient origin.
Martín I; Navarro B; Villamón E; Solano C; Serrano A; Calabuig M; Amat P; Domingo F; Abellán R; García F; Olivares MD; Chaves FJ; Tormo M; Hernández-Boluda JC
Exp Mol Pathol; 2018 Aug; 105(1):139-143. PubMed ID: 30017658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
